Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Galectin Therapeutics (NASDAQ:GALT) released its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02, MarketWatch Earnings reports.

Shares of GALT traded up $0.02 during midday trading on Thursday, reaching $2.19. The stock had a trading volume of 3,217 shares, compared to its average volume of 305,824. The firm’s 50 day moving average price is $2.29 and its 200-day moving average price is $2.48. Galectin Therapeutics has a 52 week low of $1.65 and a 52 week high of $3.85. The company has a market capitalization of $125.00 million, a P/E ratio of -5.69 and a beta of 2.04.

In other Galectin Therapeutics news, Director Gilbert F. Amelio sold 60,000 shares of the business’s stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $2.17, for a total value of $130,200.00. Following the sale, the director now directly owns 60,614 shares in the company, valued at $131,532.38. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 40.70% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate is GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Further Reading: Different Types of Derivatives

Earnings History for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with's FREE daily email newsletter.